US CDC votes to recommend GSK's Arexvy against RSV

America's public health watchdog endorsed GSK's Arexvy for use against Respiratory Syncytial Virus in adults over 60.

The US Centers for Disease Control and Prevention's Advisory Committee voted overnight to recommend the treatment.

"GSK's successful development of an RSV vaccine to help protect older adults from RSV lower respiratory tract disease (LRTD) represents a major scientific advance, resulting from years of collaboration across academia, industry, and research centres," said GSK's Chief Scientific Officer, Tony Wood.

That opened the door to more than 55m older Americans to use Arexvy for the first time.

RSV was responsible for roughly 177,000 hospitalisations and 14,000 deaths in the US each year, according to the pharmaceutical giant.

As of 0850 BST, shares of GSK were falling by 1.9% to 1,345.80p.